Telos Rx review

Every GLP-1 price on Telos Rx is a floor rather than a rate. The site publishes "as low as" $99 a month for injectable semaglutide and $139 for tirzepatide, then adds in the same block that your price depends on plan length. A floor tells you what the cheapest plan costs somebody; it does not tell you what your plan costs you.

Four products carry a published floor: tirzepatide at $139 a month, semaglutide at $99, microdosed tirzepatide at $116 — microdosing here is tirzepatide, not semaglutide — and a needle-free oral option at $9 a day. Each product page shows its figure struck through against a higher anchor, $299 for semaglutide, $399 for tirzepatide and $279 for microdosed, and the lower number is the live one. What no page shows is the plan ladder that produces it.

The plan lengths sit behind the intake, and the intake asks for your date of birth on its first screen. Reading the GLP-1 comparison hub, the semaglutide, tirzepatide, oral and microdosed product pages and the homepage on August 28, 2026 turned up no plan table, no first-month rate, no renewal price and no billing cycle anywhere on the public site. The honest position is that the rungs are undetermined — not that Telos has none, but that you cannot see one without starting an intake.

The needle-free product has become a single "Oral GLP-1" covering either semaglutide or tirzepatide, with the provider choosing the molecule and one intake covering both. It is priced "from $9 a day", footnoted to a 3-month prepaid plan for oral semaglutide. Nine dollars a day is roughly $270 a month, which is worth saying out loud, because a daily price sitting in a table beside three monthly ones invites a comparison the units do not support.

Two commitments are in writing. Pricing is flat through titration — "your monthly cost doesn't change as your clinician titrates your dose" — and you can cancel at any time with no penalties. Flat-through-titration is the more valuable of the two, because a dose climb is where a GLP-1 bill usually grows, and it means whatever number the intake quotes you should still be the number you pay at a full dose.

The menu is the widest of any provider we cover: compounded semaglutide and tirzepatide in injectable, oral and microdosed forms, alongside intranasal NAD+, recovery peptides including sermorelin, ipamorelin, CJC-1295, BPC-157 and TB-500, and bioidentical hormone therapy. All of it is compounded and none of it is FDA-approved, and several of the peptides rest on thin human evidence. The platform itself is LegitScript-certified and HIPAA-compliant, and HSA and FSA cards are accepted.

Treat the four floors as a starting point for a question, not an answer. A year at the published semaglutide floor would be $1,188 and a year of tirzepatide $1,668, but Telos never says the floor is a twelve-month figure, a three-month figure or a first-month figure, so those totals are only what the floor would come to if it held — not a price the company has quoted. The one plan length it does name anywhere is the 3-month prepay behind the oral product's $9 a day.

What goes unpublished extends past the plan rungs. Telos does not list the states it serves, names no clinician and no one in leadership, and has only a thin base of public reviews. Confirming your state is worth doing before you spend time in an intake that opens by asking your date of birth. It fits someone who wants a needle-free or microdosed route, or who wants a GLP-1 and peptides from the same certified provider, and who does not mind an intake standing between them and a price. It fits badly anyone who needs the number first. The $99 is where the pricing starts, and the only way to learn what it becomes for you is to begin the intake and keep going.